Navigation Links
Back-Up Compounds and S1P1 Lead Compounds, Assets Generated by Epix Pharmaceuticals, Inc. and Amgen, Will Be Offered for Sale at a December 8, 2011 Sealed Bid Sale

WELLESLEY HILLS, Mass., Nov. 1, 2011 /PRNewswire/ -- Joseph F. Finn, Jr., C.P.A. ("Finn"), Assignee for the Benefit of Creditors of Epix Pharmaceuticals, Inc. ("Epix"), announced today that the back-up compounds and S1P1 lead compounds, assets generated by Epix Pharmaceuticals, Inc. and Amgen, will be offered December 8, 2011 in a sealed bid sale.  

Back-up Compounds --

A total of ~640 analogs were synthesized by Epix and/or Amgen chemists to explore the SAR of several chemical series including the two lead series:  benzofurans (AMG 277) and benzothiazoles (AMG 369).  Six of these compounds were profiled in a preliminary 4d non-GLP rat toxicology study based on their attractive potency, selectivity, ADME, and efficacy profiles.  Based on these results, four compounds were profiled further in a 14d non-GLP rat toxicology study and two of these compounds were profiled in a monkey 14d non-GLP toxicology study.  

Assets included in the sale include preclinical and toxicology data related to AMG 277, AMG 369 and six backup compounds, existing inventory of these compounds (API), and related patent portfolio.

Persons interested in bidding must sign a Confidentiality Disclosure Agreement ("CDA") obtained from Finn's office -- or 781-237-8840; upon receipt of the executed CDA, applicants will receive a bid package, to be completed and returned by December 8, 2011.

About Joseph F. Finn, Jr., C.P.A.

Joseph F. Finn, Jr., C.P.A. is the founding partner of the firm, Finn, Warnke & Gayton, Certified Public Accountants of Wellesley Hills, Massachusetts.  He works primarily in the area of management consulting for distressed enterprises, bankruptcy accounting and related matters, such as assignee for the benefit of creditors and liquidating agent for a corporation.  His most recent Assignments for the Benefit of Creditors in the biotech filed include Spherics, Inc., ActivBiotics, Inc., Prospect Therapeutics, Inc. and Source MDx.

For further information, please contact Joseph F. Finn, Jr., C.P.A. at 781-237-8840 or

SOURCE Joseph F. Finn, Jr., C.P.A.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Amira Pharmaceuticals Announces Initial Positive Phase 1 Clinical Data for AM461, A Back-Up to Amiras Lead DP2 Antagonist, AM211
2. Contractual Agreements Revealed for S1P1 Lead Compounds, AMG 369 and AMG 277, Offered for Sale at a December 8, 2011 Sealed Bid Sale
3. S1P1 Lead Compounds, AMG 369 and AMG 277, Will Be Offered for Sale at a December 8, 2011 Sealed Bid Sale
4. Bayer to Present New Data Evaluating Investigational Oncology Compounds at 2011 ECCO-ESMO Congress
5. Cornerstone Pharmaceuticals Announces The Journal of Molecular Medicines Publication of Research Showing Selective Inhibition of Cancer Cell Energy Metabolism With Its Novel Lipoate Derivative Compounds
6. Vantia Therapeutics Raises £4 Million to Fund Clinical Development of its Lead Compounds
7. Zealand Pharma and Boehringer Ingelheim Enter Into a Licence and Collaboration Agreement to Advance Novel Compounds to Treat Type-2 Diabetes and Obesity
8. Novartis highlights extensive data on numerous compounds at ASCO in multiple cancers, including Phase III studies in GIST and myelofibrosis
9. Bayer to Present Data on Investigational Oncology Compounds at 2011 Annual Meeting of the American Society of Clinical Oncology (ASCO)
10. Intra-Cellular Therapies and Takeda Enter into Worldwide Collaboration to Develop and Commercialize Compounds for Schizophrenia
11. Caliper Continues Participation in EPAs Expanded ToxCast Program; Receives Remaining Phase II Compounds for Screening in Fourth Quarter
Post Your Comments:
(Date:11/30/2015)... , Nov. 30, 2015   VolitionRx Limited (NYSE ... diagnostic tests for a broad range of cancer types and ... LD Micro Conference, which will be held December 1 - 3 ... from VolitionRx will be David Kratochvil , Chief Financial ... of Investor Relations. ® blood-based tests for ...
(Date:11/30/2015)... , November 30, 2015 Elbit ... the "Company") announced today that it was informed by InSightec ... Drug Safety (MFDS) has approved its Exablate Neuro system ... --> --> Insightec,s Exablate Neuro ... alternative that combines two technologies: Focused Ultrasound, which is ...
(Date:11/29/2015)... CHICAGO , Nov. 29, 2015  The GE Health ... annual Radiological Society of North America ... exclusively for the healthcare industry, the new cloud ecosystem and ... and collaboration across care pathways and multidisciplinary teams – both ... Immelt , Chairman and CEO of GE. "As the digital ...
Breaking Medicine Technology:
(Date:11/30/2015)... , ... November 30, 2015 ... ... Inc. are pleased to announce their strategic partnership at the Radiological Society ... Transcription Service, Inc., and Winscribe, global providers of cutting-edge dictation and speech-enabled ...
(Date:11/30/2015)... ... 2015 , ... World Patent Marketing , a vertically ... invention that provides an economical and easy way of gaining customized curtains. , ... 2.6%," says Scott Cooper, CEO and Creative Director of World Patent Marketing. "There ...
(Date:11/29/2015)... ... November 29, 2015 , ... ... Institute of Ultrasound in Medicine! , AIUM ultrasound practice accreditation is a ... or exceed nationally recognized standards in the performance and interpretation of diagnostic ...
(Date:11/29/2015)... Los Angeles, Ca (PRWEB) , ... November 29, 2015 , ... ... from the American Board of Ophthalmology on November 25th 2015. Peer Certification ... in the field of his specialty. Certification in Ophthalmology is first obtained after the ...
(Date:11/29/2015)... ... ... Effective immediately, every single IguanaMed scrub style will be available at Target via ... “Buy One Scrub Set, Get the 2nd Scrub Set 50% Off” for a limited ... price. , IguanaMed’s mission is to outfit every healer around the world ...
Breaking Medicine News(10 mins):